102.61
Biontech Se Adr Aktie (BNTX) Neueste Nachrichten
Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
Aberdeen Group plc Grows Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Mirae Asset Global Investments Co. Ltd. Purchases 533 Shares of BioNTech SE Sponsored ADR $BNTX - Defense World
Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead - The Globe and Mail
Shell Asset Management Co. Buys 5,398 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE Sponsored ADR $BNTX Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
Slow Capital Inc. Sells 3,415 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Platinum Investment Management Ltd. Invests $1.58 Million in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Why BioNTech Stock Jumped by Nearly 4% on Wednesday - The Globe and Mail
TB Alternative Assets Ltd. Trims Stock Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
JPMorgan Chase & Co. Issues Positive Forecast for BioNTech (NASDAQ:BNTX) Stock Price - Defense World
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Baader Bank Aktiengesellschaft Acquires 9,040 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
37,500 Shares in BioNTech SE Sponsored ADR $BNTX Bought by Swedbank AB - MarketBeat
Rep. Val T. Hoyle Sells BioNTech SE Sponsored ADR (NASDAQ:BNTX) Shares - MarketBeat
Lingohr Asset Management GmbH Sells 36,209 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Weekly Market Update: Stocks Gain 1.25%, Led by Technology and Communication Services - Morningstar
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises - Ariva
BioNTech’s New PDAC Study: A Potential Game-Changer in Cancer Treatment? - MSN
BioNTech (NASDAQ:BNTX) Sees Strong Trading VolumeStill a Buy? - MarketBeat
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):